ClinicalTrials.gg
CompletedNCT00272545Updated Sep 6, 2013

Effectiveness of a Normalization of Eating Intervention Program for Treating Women With Eating Disorders

An interventional study of Normalization of Eating (NOE) and Treatment As Usual (TAU) in Eating Disorders, sponsored by Drexel University. Completed at 1 site in United States. Open to female participants aged 15 Years to 40 Years. Per ClinicalTrials.gov, last updated 2013-09-06.

Sponsored by Drexel University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Non-randomized
Ages
15 Years to 40 Years
Sex
Female
01

Study summary

This study will evaluate the effectiveness of a new approach to a normalization of eating program, based on principles of cognitive-behavioral therapy, in treating women with anorexia nervosa or bulimia nervosa.

Read the detailed description

Eating disorders are real, treatable medical illnesses. They are often characterized by disturbances in eating behavior, such as drastic reduction of food intake or extreme overeating, as well as feelings of distress or extreme concern about body shape or weight. The two main types of eating disorders are anorexia nervosa and bulimia nervosa. A third type, binge-eating disorder, is pending approval as a formal psychiatric diagnosis. Eating disorders frequently develop during adolescence or early adulthood, and they occur more often in females than in males. Studies have shown cognitive behavioral therapy (CBT) to be the most effective approach to treating eating disorders. However, the applicability of these findings to clinical settings and intensive outpatient therapy programs (IOPs) remains unknown. This study will evaluate the effectiveness of a new approach to a normalization of eating (NOE) program, based on principles of CBT, in treating women with anorexia nervosa or bulimia nervosa.

Participants in this open-label study will be assigned to receive either treatment-as-usual (TAU) or NOE. Participants admitted to the study in the first 8 months of the trial will receive TAU. Those admitted after the first 8 months will take part in the NOE program. Participants may begin receiving treatment as soon as they enter the study and will continue receiving their assigned treatments for 6 weeks. All participants in the NOE group will be required to report to the study site three evenings a week. They will receive individual therapy, as well as take part in group and family therapy sessions. In addition, they will be supervised while eating a meal. Body weight, results of the Eating Disorders Examination and the Structured Clinical Interview for DSM-IV Axis I disorders, and self-report measures will be assessed post-treatment and at the Month 6 follow-up visit.

Note: Participants are recruited from the Renfrew Center's outpatient programs located in the Philadelphia area. Individuals outside of Renfrew cannot volunteer for this study. For more information about the Renfrew Center's inpatient or outpatient treatment programs, please call 1-800-RENFREW.

02

Conditions studied

  • Eating Disorders

Keywords

  • Anorexia Nervosa
  • Bulimia Nervosa
  • Cognitive Behavioral Therapy
03

In context

Feeding and Eating Disorders

753 studies on the registry are indexed under Feeding and Eating Disorders; 160 are open to participants now.

This study's enrollment of 280 is above the median of 74 across 551 interventional studies indexed under Feeding and Eating Disorders.

Browse Feeding and Eating Disorders studies →

Lead sponsor

Drexel University is the lead sponsor of 113 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of an eating disorder or eating disorder not otherwise specified (except for binge eating disorder), as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association
  • Agrees to remain in IOP treatment for at least 3 weeks
  • Seeking treatment in one of the Renfrew Center's outpatient programs located in the Philadelphia area

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of eating disorder not otherwise specified, including binge eating disorder
  • Diagnosis of a psychotic disorder
  • Transferred to inpatient treatment during the IOP stay because of worsening health
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (actual)

Study arms

  • Experimental
    1

    Participants will receive the normalization of eating program

    Behavioral: Normalization of Eating (NOE)

  • Active comparator
    2

    Participants will receive treatment as usual

    Behavioral: Treatment As Usual (TAU)

Interventions

  • BehavioralNormalization of Eating (NOE)

    The NOE is a 6-week program based on principles of CBT. Participants will receive individual therapy, as well as take part in group and family therapy sessions. In addition, participants will be supervised while eating meals.

  • BehavioralTreatment As Usual (TAU)

    Treatment as usual will include standard care for a person with an eating disorder.

06

What researchers measure

Primary outcomes

  1. Body weight

    Time frame: Measured at baseline, discharge, and 6 month follow-up

  2. Structured Clinical Interview

    Time frame: Measured at baseline

  3. Self-report

    Time frame: Measured at baseline, discharge, and 6 month follow-up

  4. Eating Disorders Examination

    Time frame: Measured at baseline, discharge, and 6 month follow-up

07

Study locations

1 site
  • The Renfrew Center of Radnor
    Radnor, Pennsylvania 19087, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00272545
Lead sponsor
Drexel University
Responsible party
Sponsor
First posted
Jan 6, 2006
Start date
Jan 2006
Primary completion
Feb 2009
Completion
Feb 2009
Last update
Sep 6, 2013

Study contacts

Michael R. Lowe, PhD
principal investigator · Drexel University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion